Immunocore

Immunocore is a privately owned, clinical-stage, UK-based biotechnology company, focused on the discovery and development of novel T cell receptor-based drugs to treat diseases with a high unmet need, including cancer and viral disease. The Company’s world-leading expertise in engineering T Cell Receptors (TCRs) and linking them to an antibody fragment (scFv) known as anti-CD3, has led to its first product candidate, IMCgp100, entering clinical trials in patients with metastatic melanoma. The proprietary T Cell Receptor technology platform is well validated and can easily be manufactured for clinical and commercial supply in microbial systems.
Company growth
Type
Private
HQ
Milton, GB
Size (employees)
217 (est)+8%
Immunocore is headquartered in Milton, GB

Key People at Immunocore

Eliot Forster

Eliot Forster

CEO
Christina Coughlin

Christina Coughlin

Chief Medical Officer
Bent Jakobsen

Bent Jakobsen

Chief Scientific Officer
Eva-Lotta Allan

Eva-Lotta Allan

Chief Business Officer
Namir Hassan

Namir Hassan

Director of Translational Research & Development
Henrik Sorensen

Henrik Sorensen

Head of Alliance Management

Immunocore Office Locations

Immunocore has office in Milton
Milton, GB

Immunocore Metrics

Immunocore Summary

Total Funding

$320 M

Latest funding size

$320 M

Time since last funding

over 1 year

Investors

We estimate that Immunocore's latest funding round in July 2015 was $320 M. In total, Immunocore has raised $320 M

Immunocore Financials

We estimate that Immunocore's revenue is £6.38 M in FY, 2014 which is 211.94% increase from the previous period.
FY, 2014FY, 2013

Revenue

£6.38 M£2.05 M

Revenue growth, %

211.9%

Immunocore Online Presence

Immunocore Company Life

You may also be interested in